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RESEARCH ARTICLE
Plasma endotoxin core antibody 
concentration and linear growth are unrelated 
in rural Malawian children aged 2–5 years
Nicole Benzoni1, Poonum Korpe2, Chrissie Thakwalakwa3, Ken Maleta3, Kevin Stephenson4, Micah Manary5  
and Mark Manary1,6*
Abstract 
Background: Environmental enteropathy is subclinical inflammation of the upper gastrointestinal tract associated 
with reduced linear growth in developing countries. Usually investigators have used biopsy or a dual sugar absorp-
tion test to assess environmental enteropathy. Such tests are time and resource intensive, restricting their utility as 
screening methods. Serum endotoxin core antibody (EndoCab) concentration is a potential indicator of intestinal 
inflammation and integrity, and thus may be useful to predict environmental enteropathy. We analyzed the associa-
tion of serum EndoCab levels versus linear growth and lactulose-mannitol assay results in 2–5 year old rural Malawian 
children.
Methods: This was an observational study of 388 rural, asymptomatic Malawian children who had anthropometric 
measurements taken at least every 3 months since birth. In June and July 2011, dual sugar permeability tests were 
performed and serum samples were drawn for EndoCab assays. Pearson correlation, Student’s t test and multivariable 
linear regression were used to compare ln EndoCab concentrations with height-for-age z scores (HAZ) at time of sam-
pling and 3 months later. Identical analysis was also performed for ln EndoCab versus measurements from dual sugar 
permeability testing performed in conjunction with serum sampling. In a subgroup of children with anthropometric 
data in the months prior to serum sampling, Pearson correlation was used to estimate the relationship between ln 
EndoCab and recent linear growth.
Results: Ln EndoCab concentrations were not correlated with HAZ at time of measurement (B = −0.078, P = 0.14) 
nor change in HAZ over the subsequent 3 months HAZ (B = −0.018, P = 0.27). EndoCab concentration was not asso-
ciated with %lactulose excretion (B < 0.001, P = 0.98) nor the lactulose:mannitol ratio (B = 0.021, P = 0.62). Subgroup 
analysis also did not reveal any significant association between EndoCab and recent growth.
Conclusion: EndoCab titers were not correlated with measurements of growth or intestinal permeability in rural pre-
school aged Malawian children.
Keywords: Endotoxin core antibody, Environmental enteropathy, Growth, Malawi
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Background
Stunting, defined as stature less than two standard devia-
tions below the median height-for-age, affects an esti-
mated one in four children worldwide [1]. Stunted children 
experience reductions in physical capability and school 
performance as well as modest compromises in immune 
function [2]. Randomized trials of multiple micronutri-
ent provision, dietary supplementation and antimicrobial 
interventions to reduce the infectious disease burden do 
not substantially reduce stunting [3]. Stunting is thought 
to be caused by chronic malnutrition and diarrheal illness; 
gastrointestinal inflammation has been implicated as an 
important additional contributor [3–5].
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Environmental enteropathy (EE) is a subclinical con-
dition with T-cell infiltration of the duodenum and jeju-
num, decreased villous height and increased crypt depth 
[3, 6, 7]. Children with EE have increased intestinal per-
meability and reduced nutrient absorption. EE has been 
associated with the reduced linear growth and cogni-
tive function [5, 8]. The etiology of EE is unknown [3]. 
Historically, diagnosis of EE was determined via small 
bowel biopsy revealing the aforementioned architectural 
changes. Biopsy is too costly and invasive to serve as a 
screening tool in developing countries where EE is preva-
lent [7].
Dual sugar absorption, or lactulose:mannitol (L:M), 
testing provides a less invasive measure of gut health 
at a single point in time [9]. Increased %lactulose (%L) 
excretion suggests impaired intestinal barrier function; 
decreased %mannitol (%M) excretion correlates with 
decreased functional intestinal surface area [10]. The L:M 
test is time and resource intensive and therefore often 
difficult to accomplish in settings where stunting is per-
vasive. The reliability and validity of L:M as a measure of 
intestinal health is contingent upon the clinical protocol 
for test administration and the analytical method used to 
quantitate sugar concentrations [11, 12]. Recent research 
has focused on developing an alternative, practical bio-
marker for EE [3, 11, 12].
Serum titer of endotoxin core antibody (EndoCab) 
showed promising results in reflecting linear growth and 
intestinal function among Gambian infants, prompting 
further analysis of EndoCab as a candidate biomarker [5, 
11]. EndoCab is produced in response to the lipopoly-
saccharide component of gram-negative bacteria’s cell 
wall after systemic exposure to enteric bacteria [3]. Bac-
terial degradation products may translocate across the 
impaired gastrointestinal mucosal barrier and induce 
EndoCab formation. It was thus hypothesized that Endo-
Cab levels may be a cumulative measure of EE burden in 
affected children [11]. Recent analyses of EndoCab versus 
growth and permeability revealed conflicting findings in 
Bangladeshi and Zimbabwean infants <2 years old and no 
relationship to concurrent height measurements in young 
Bangladeshi children [8, 13, 14]. Thus further research is 
required to determine the utility of EndoCab measure-
ments, particularly in children over 2 years of age.
Among a population of 2–5  year old rural Malawian 
children in whom we have previously demonstrated an 
association between growth and %L, we assessed Endo-
Cab levels within collected serum samples [10]. This 
observational study tests the hypothesis that EndoCab is 
inversely correlated to cumulative linear growth as well 




A total of 418 healthy children aged 2–5  years were 
recruited from five rural subsistence farming areas 
in southern Malawi in June and July of 2011 from a 
population enrolled in a longitudinal gut microbiome 
study [10, 15]. These children consumed a diet primar-
ily of maize and legumes and had growth monitored 
every 2–3  months since birth. Of the original cohort, 
388 children had serum samples collected for EndoCab 
assessment and were eligible for this analysis. Exclusion 
criteria included any chronic debilitating illness, includ-
ing known HIV infection or obvious congenital abnor-
malities, evidence of acute malnutrition, and a recent 
history or current case of diarrhea or hematochezia. Evi-
dence for the exclusion criteria was sought by interview, 
review of the child’s heath record and physical examina-
tion, including anthropometry.
Written and oral consent was obtained from every 
subject’s caregiver prior to participation. The study was 
approved by the College of Medicine Research Ethics 
Committee of the University of Malawi, the Washing-
ton University Human Research Protection Office, and 
the Baylor College of Medicine Human Investigations 
Review Board.
Participation
Information regarding demographics, household 
hygienic practices and the child’s recent health was 
obtained at enrollment prior to serum collection through 
in-person interview with the child’s caregiver. Individual 
dietary diversity scores (IDDS) were assessed at baseline 
[16]. Anthropometric measurements throughout the 
study were obtained following procedures adapted from 
the Food and Nutrition Technical Assistance (FANTA) 
project [17]. Weight was measured using an electronic 
scale to the nearest 5  g. Length was measured to the 
nearest 0.2 cm using a rigid length board three separate 
times and the three values were averaged [17]. Age was 
calculated as months since the child’s birthdate, based on 
each child’s Malawian Health Passport, an official docu-
ment issued by the Malawian government containing the 
child’s date of birth and vaccination record [18]. Approxi-
mately 3  months after the initial visit, a second set of 
anthropometric measurements and a survey of recent 
child health were collected.
A dual sugar absorption test was conducted at the ini-
tial visit to assess intestinal function and integrity. Car-
egivers were directed not to feed the child for 12 hours 
prior to participation during a preparatory meeting, and 
asked to come to the study site before 6 am. Children 
were encouraged to drink water to facilitate urination 
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and mothers were instructed not to breastfeed their 
children during this time. Children were given the non-
metabolized sugars lactulose (5  g) and mannitol (1  g) 
dissolved in 100 mL of water. A complete 4 h urine col-
lection was made and 10  mg merthiolate was added to 
the urine collection cup to limit bacterial degradation of 
the sugars. The total urine volume was measured and a 
4 mL aliquot was transferred to a cryovial, flash frozen in 
liquid nitrogen, and transported at −80°C to Baylor Col-
lege of Medicine.
A serum sample was drawn during the dual sugar 
absorption testing, transferred to a clot activator tube, 
kept cool on ice while the children completed their urine 
collection, and then spun at 3,000 rpm for 15 min. Serum 
was transferred to a clean cryovial and frozen in a −80°C 
freezer. These sera were transferred to the University 
of Virginia, Charlottesville, VA as a batch for EndoCab 
analyses.
Laboratory analyses
Concentrations of lactulose and mannitol in the urine 
specimens were analyzed by high pressure liquid chro-
matography as has been previously described [19]. The 
assays are sensitive to 1  μg/mL lactulose and mannitol 
and the coefficient of variation (CV) for this sample set 
was ≤5% [19].
Serum was tested using a commercially available Endo-
Cab IgG ELISA assay (Hycult Biotech Inc., The Nether-
lands) chosen from the same lot and purchased at the 
same time. Prior to testing, serum samples were brought 
to room temperature and the assay was performed per 
package insert. Samples were run in duplicate and mean 
absorbance values measured using a Biotek Synergy H4 
Plate Reader. A standard curve with good curve fit was 
generated using Gen5 software (BioTek Instruments, Inc. 
USA).
Data analyses
Data were double entered into a Microsoft Access data-
base and cleaned by correcting any discrepancies iden-
tified by double entry, using original collection forms as 
reference. Anthropometric indices based on the World 
Health Organization’s 2006 Child Growth Standards 
were calculated using Anthro v 3.1 (WHO, Geneva). 
Linear growth was defined as the difference between 
length at serum sampling and at follow-up approximately 
3  months later. All analyses were conducted using SAS 
System for Windows, Version 9.4 (SAS Institute Inc. 
Cary, NC, USA). Differences were considered statistically 
significant at P < 0.05, unless otherwise noted.
Urinary excretion of lactulose and mannitol (as per-
centage of dose administered) and L:M ratio were cal-
culated. Similar to previous analyses, an L:M ratio >0.10 
was defined as abnormal, based on reference values from 
healthy children in developed countries [20]. Normality 
was assessed for continuous variables using Shapiro–Wilk 
test, variables with P  >  0.05 were considered normally 
distributed [21]. Variables with non-normal distribution, 
including EndoCab, %L and L:M values, were approxi-
mated to a normal distribution by log transformation.
Anthropometric and permeability measures were 
divided approximately into quartiles to compare mean 
ln EndoCab levels amongst children with similar health 
metrics. Children were divided into quartiles defined by 
(1) height-for-age z score (HAZ), (2) change in HAZ, (3) 
L:M ratio and (4) %L excretion. For each set, one-way 
analysis of variance for interquartile mean ln EndoCab 
was conducted using the Tukey–Kramer HSD test [22].
Bivariate parametric correlation tests were conducted 
to identify statistically significant predictors of linear 
growth and intestinal permeability. Pearson correlation 
testing was used to compare the height and permeability 
measures with continuous variables and Student’s t test 
to compare with binary variables. Separate analyses were 
performed for four dependent continuous variables: (1) 
HAZ at the time of serum sampling, (2) change in HAZ 
3 months later, (3) ln L:M ratio and (4) ln %L excretion.
To determine ln EndoCab’s ability to predict linear 
growth after taking into account other factors, backward 
multivariable linear regression modeling was conducted. 
Independent variables with a Pearson product-moment 
correlation coefficient or t-statistic with an associated 
P value <0.20 were eligible for inclusion in each respec-
tive model. Other independent predictor variables con-
sidered for inclusion were dietary diversity, sanitation 
and socioeconomic characteristics collected at baseline 
and previously considered during regression modeling 
in the overall Malawian cohort [10]. These included the 
child’s age in months at serum sampling, gender, family 
ownership of a bicycle, whether the child’s house had a 
metal roof and previous treatment with therapeutic food. 
Additional anthropometric measurements measured at 
serum sampling, mid-upper arm circumference Z-score 
(MUACZ) and weight-for-age Z-score (WAZ). were 
only considered in the model for change in HAZ over 
3 months. As the primary variable of interest, ln EndoCab 
was included regardless of statistical significance. Multi-
collinearity testing was conducted by measuring variance 
inflation factor (VIF) amongst assessed variables. A VIF 
>5 was considered suggestive of multicollinearity. Vari-
ables were eliminated from the model if P > 0.05.
A subgroup analysis was undertaken to investigate a 
possible relationship between ln EndoCab and linear 
growth in the months prior to antibody measurement, 
which would suggest that serum EndoCab reflects previ-
ous growth trends. Children were eligible for inclusion in 
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the subgroup if anthropometric data was available for the 
6  months preceding serum sampling. Pearson correla-
tion analysis was performed between HAZ or change in 
HAZ (from 3 to 6 months prior to serum sampling) and 
ln EndoCab concentration.
Results
Of the 388 children included in this analysis, 301 (78%) 
were stunted and 340 (88%) had an L:M ratio sugges-
tive of EE (Table 1). The average EndoCab concentration 
was 74.2 GMU/mL, nearly twice the mean expected titer 
for children with normal intestinal absorption and bar-
rier function, based on titers from healthy UK children 
[5]. No statistically significant difference was observed 
in average ln EndoCab concentrations amongst children 
stratified into quartiles by (1) HAZ at serum sampling, 
(2) change in HAZ over 3 months, (3) L:M ratio or (4) %L 
(Tukey–Kramer test) [22].
Pearson product-moment correlation coefficients 
were calculated to estimate the relationship between ln 
EndoCab and linear growth as well as dual sugar absorp-
tion tests (Table 2). There was no statistically significant 
association between ln EndoCab and HAZ (r = −0.048, 
P = 0.35) or change in HAZ (r = −0.078, P = 0.12). Com-
parison of permeability measures to ln EndoCab revealed 
no significant relationship with either ln %L (r  <  0.001, 
P = 0.99) or ln L:M (r = 0.025, P = 0.64).
After multivariable regression modeling, ln EndoCab 
concentration was not found to be a significant predic-
tor of HAZ (B = −0.078, P =  0.14) or change in HAZ 
(B  =  −0.018, P  =  0.27) as shown in Table  2. Thus a 
1-unit increase ln EndoCab is associated with 0.078 SDs 
decrease in HAZ and 0.018 SDs decrease in change in 
HAZ over 3  months, after adjusting for other variables 
within the model. These changes did not reach statisti-
cal significance. Neither was ln EndoCab predictive of 
measures of gut integrity and permeability, either via ln 
%L (B < 0.001, P = 0.98) or ln L:M (B = 0.021, P = 0.62). 
Multicollinearity testing suggested very low levels of col-
linearity existed between variables (VIF <5). Covariates 
found to be statistically significant in each final model are 
presented as a footnote to Table 2.
After excluding children with less than 6  months of 
anthropometric data prior to serum sampling, a sub-
group of 103 children remained to analyze a correlation 
between ln EndoCab and recent growth. This subgroup 
of children were on average younger (31.5  ±  3.5  mos), 
had higher EndoCab levels (79.6 ± 135.6 GMU/mL) and 
slightly lower HAZ (−3.0 ± 1.0) compared to the larger 
study population. No relationship was found between ln 
EndoCab and linear growth from either 3 or 6  months 
prior to its measurement (Pearson Correlation, Table 3).
Discussion
In a group of rural, immunocompetent Malawian chil-
dren aged 2–5 years, EndoCab was not found to be asso-
ciated with preceding or future linear growth, nor was it 
associated with intestinal permeability measurements. 
An association between the urinary %L at and linear 
growth was previously demonstrated in this same study 
population [10]. The magnitude of the titers of Endo-
Cab from Malawian children and children in the United 
Kingdom suggest, but do not prove, that there is more 
exposure in Malawi to enteric bacteria than in the United 
Kingdom. The testing conditions and laboratory methods 
Table 1 Characteristics of  rural Malawian children 
enrolled in EndoCab analysis, n = 388
Characteristic Mean (±SD) or N (%)
Age, months 40.5 (±8.6)
Male 182 (47%)
Endotoxin antibody, GMU/mL 74.2 (±100.7)
Height-for-age, z score −2.80 (±1.1)
Change in HAZ 3 months after EndoCab analyses 0.3 (±0.3)
Weight-for-age, z score −1.5 (±0.9)




 L:M ≥0.10 340 (88%)
 L:M <0.10 48 (12%)
House has a metal roof 102 (26%)
Child cleanses hands with soap after stooling 192 (50%)
Child previously treated for malnutrition 12 (4%)
Table 2 Pearson correlation and  regression models pre-
dicting HAZ, change in HAZ over  3 months and  intestinal 
permeability markers using serum ln EndoCab, n = 388
Variables included in the final models: HAZ, adj R2  = 0.09 (age in mos at serum 
sampling, bike ownership, metal roof on house, mother as primary caretaker, 
long distance to water, soap use); change in HAZ, adj R2 = 0.02 (age in mos at 
sampling, initial WAZ, IDDS, bike ownership, animals sleep in house); ln %L, adj 
R2 = 0.01 (male gender, pit latrine use); ln L:M, adj R2 = 0.11 (age in mos at sam-
pling).
r, Pearson product-moment correlation coefficient for ln EndoCab; B, stand-
ardized regression coefficient (change in respective measurement per 1-unit 
change ln EndoCab, adjusting for other co-variables); SE, standard error.
† P value associated with B for ln EndoCab.
a Change in HAZ from time of sampling to 3 months later.
r B (SE) P value†
Height-for-age, Z-score −0.047 −0.078 (0.05) 0.14
Change in height-for-age, Z scorea −0.078 −0.019 (0.02) 0.27
%Lactulose 0.025 <0.001 (0.06) 0.98
Lactulose:mannitol <0.001 0.021 (0.04) 0.62
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were not standardized in these two observations, so a 
definitive comparison cannot be made.
An intact gastrointestinal tract provides an essential bar-
rier between a child and his or her intestinal microbes. 
Damage to its integrity decreases a child’s ability to prevent 
systemic exposure to inflammatory bacterial byproducts 
[3]. It has been hypothesized that serum EndoCab con-
centration may reflect cumulative gastrointestinal insult, 
and therefore the burden of EE, over a child’s lifetime [5, 
11]. Our data analysis does not support the notion that, in 
2–5 year old rural African children, EndoCab concentra-
tion reflects the lifetime or recent severity of EE. Our study 
is limited, however, in that EndoCab was measured at a 
single point in time. Since EndoCab is thought to repre-
sent chronic intestinal damage, a single IgG measurement 
may limit comparability to L:M or %L, which are point 
estimates of intestinal permeability. The utility of EndoCab 
may have been greater if IgM, an acute phase reactant, was 
measured, or if multiple measurements had been made.
Increased EndoCab levels suggest a systemic inflam-
matory response, which has been shown to limit linear 
growth in children [7]. Previous analyses of Gambian and 
Bangladeshi infants <2 years old identified an association 
between EndoCab and HAZ, but a case–control study in 
stunted Zimbabwean infants <18  months old found no 
such correlation [5, 13, 14]. Our study enrolled children 
between 2 and 5 years of age, therefore limiting compa-
rability to analyses of younger children. In a study per-
formed in older Bangladeshi children (1–4 years of age) 
analysis of concurrent HAZ and EndoCab measurements 
revealed no significant relationship [8]. The positive cor-
relation found in some studies of younger children may 
be due to a temporal relationship between antibody pro-
duction and exposure to enteric antigens. Younger chil-
dren have had fewer exposures to endotoxin and thus 
each exposure, in the setting of impaired intestinal bar-
rier in EE, results in increased EndoCab production. 
Older children may not exhibit changes in EndoCab con-
centration unless there is a substantial additional insult 
to the barrier function of the gut.
Discerning reasons for differences across is compli-
cated. Recent changes in the production of the EndoCab 
ELISA assay limits comparability between initial and 
current analyses [11]. The coefficient of variation (CV) 
was also not assessed in this study, thus it is difficult quan-
tify sample dispersion within the EndoCab assay. Nor has 
CV consistently been reported in previous articles. Intra-
assay and inter-assay CVs need to be analyzed to ensure 
that measured serum EndoCab concentration can be 
compared within and between studies. Finally, the assay 
itself has limitations as a potential biomarker and screen-
ing tool. Serum samples for EndoCab can be collected rel-
atively quickly, an advantage over the time intensive L:M 
assay, but antibody measurement requires the collection, 
storage and separation of blood, which is cumbersome 
and invasive in the setting where EE is prevalent. The gen-
eralizability of our findings are limited to rural African 
children, care should be taken to extrapolate these find-
ings urban children and to regions outside Africa.
Conclusion
The results of this study demonstrate that EndoCab is not 
a sensitive biomarker of either linear growth or intesti-
nal permeability in rural African children between 2 and 
5 years of age, suggesting it is not a good biomarker of EE 
beyond infancy in this population. Research focus may 
shift towards consideration of other potential EE bio-
markers in older children that reflect immune response 
to enteric antigens, such as antiflagellin antibody, soluble 
CD14 or intestinal fatty acid binding protein [23, 24].
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